The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Svetozarskiy S.N.

Volga District Medical Centre

Kopishinskaya S.V.

Kirov State Medical University

Ruina E.A.

Privolzhsky Research Medical University

Antipenko E.A.

Privolzhsky Research Medical University

Clinical phenotypes of optic nerve damage in patients with neuromyelitis optica spectrum disorder

Authors:

Svetozarskiy S.N., Kopishinskaya S.V., Ruina E.A., Antipenko E.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2023;139(2): 61‑67

Read: 1976 times


To cite this article:

Svetozarskiy SN, Kopishinskaya SV, Ruina EA, Antipenko EA. Clinical phenotypes of optic nerve damage in patients with neuromyelitis optica spectrum disorder. Russian Annals of Ophthalmology. 2023;139(2):61‑67. (In Russ.)
https://doi.org/10.17116/oftalma202313902161

Recommended articles:
Eculizumab in the treatment of neuromyelitis optica spectrum diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):60-65
Glymphatic system in health and disease: a narrative review. Burdenko's Journal of Neurosurgery. 2025;(4):112-118

References:

  1. Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019;19(2):169-176.  https://doi.org/10.7861/clinmedicine.19-2-169
  2. Chen JJ, Pittock SJ, Flanagan EP, Lennon VA, Bhatti MT. Optic neuritis in the era of biomarkers. Surv Ophthalmol. 2020;65:12-17.  https://doi.org/10.1016/j.survophthal.2019.08.001
  3. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280.  https://doi.org/10.1186/s12974-016-0718-0
  4. Salama S, Khan M, Shanechi A, Levy M, Izbudak I. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler. 2020;26(14): 1854-1865. https://doi.org/10.1177/1352458519893093
  5. Gospe SM 3rd, Chen JJ, Bhatti MT. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye (Lond). 2021; 35(3):753-768.  https://doi.org/10.1038/s41433-020-01334-8
  6. ZhangBao J, Zhou L, Li X, et al. The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients. J Neuroimmunol. 2017;302:49-55.  https://doi.org/10.1016/j.jneuroim.2016.11.010
  7. Huang Y, Zhou L, ZhangBao J, et al. Peripapillary and parafoveal vascular network assessment by optical coherence tomography angiography in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. Brit J Ophthalmol. 2018;103(6):789-796.  https://doi.org/10.1136/bjophthalmol-2018-312231
  8. Felix C, Levin M, Verkman A. Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G. J Neuroinflammation. 2016;13:275.  https://doi.org/10.1186/s12974-016-0746-9
  9. Srikajon J, Siritho S, Ngamsombat C, Prayoonwiwat N, Chirapapaisan N; Siriraj Neuroimmunology Research Group. Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis. Mult Scler J Exp Transl Clin. 2018;4(3):2055217318791196. https://doi.org/10.1177/2055217318791196
  10. Zhao X, Qiu W, Zhang Y, et al. A prospective case-control study comparing optical coherence tomography characteristics in neuromyelitis optica spectrum disorder — optic neuritis and idiopathic optic neuritis. BMC Ophthalmology. 2018;18:247.  https://doi.org/10.1186/s12886-018-0902-3
  11. Traub J, Häusser-Kinzel S, Weber MS. Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients. Int J Mol Sci. 2020;21(14):5021. https://doi.org/10.3390/ijms21145021
  12. Palace J, Lin DY, Zeng D, Majed M, Elsone L, Hamid S, Messina S, Misu T, Sagen J, Whittam D, Takai Y, Leite MI, Weinshenker B, Cabre P, Jacob A, Nakashima I, Fujihara K, Pittock SJ. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019; 142(5):1310-1323. https://doi.org/10.1093/brain/awz054
  13. Traub J, Husseini L, Weber MS. B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders. Pharmaceuticals (Basel). 2021;14(1):37.  https://doi.org/10.3390/ph14010037
  14. Barnett M, Prineas J, Buckland M, Parratt J, Pollard J. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012;18(1):108-112.  https://doi.org/10.1177/1352458511421185
  15. Ayzenberg I, Schollhammer J, Hoepner R, et al. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol. 2016;263(3):575-582.  https://doi.org/10.1007/s00415-015-7991-1

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.